NetworkNewsBreaks – Zenosense, Inc. (ZENO) Devel

NetworkNewsBreaks – Zenosense, Inc. (ZENO) Developing Technology to Deliver High-sensitivity Laboratory Accuracy in Emergency Settings

Healthcare technology company Zenosense (OTC: ZENO) is currently developing its MIDS Cardiac handheld diagnostic technology to provide rapid cardiac biomarker tests in emergency settings. A recent article discussing the company reads: “MIDS goes beyond the optical technology used by most immunoassay tests. The analytical sensitivity gap between central laboratory testing platforms and existing POC testing devices is significant as this bulky optical technology has not been successfully miniaturized into high sensitivity capable, handheld devices. In contrast, the MIDS technology uses highly sensitive, custom-built “Hall Effect” magnetic sensors that allow it to detect extremely low levels of magnetic field disturbance caused by immunoassay beads. As the recent results indicate, this is expected to deliver Gold Standard, true high-sensitivity laboratory testing at the POC with results available in minutes — enabling high-sensitivity laboratory accuracy in emergency settings for the first time.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer